isotherms of the binding of the anthracyciine antibiotic, adriamycin (adriblastin), to dna histone complexes was studied by means of spectroscopic analysis. the results indicated that: (a) binding of adriamycin to histones reduced the interaction of histones with dna, (b) binding of the drug to dna did not change the binding affinity of histone to dna and, (c) in the explored binding range of r

treatment related acute myeloid leukemia (t-aml) is well documented phenomenon after chemotherapy. in this subgroup of patients acute promyelocytic leukemia (apml) due to delayed complication of using anthracycline is very rare occurrence. very few cases are reported in world literature. we are reporting a rare case of occurrence of t-apml in cured breast cancer patient treated with doxorubicin...

in this study calf thymus chromatin was fractionated into active (s1 and s2) and inactive (p 2) chromatin. then the interaction of an anthracyc1ine antibiotic, adriamycin, with these fractions was investigated employing absorption and difference uv nis spectroscopy and sds and agarose gel electrophoreses. the results suggest that the binding of adriamycin to the s 1 fraction is slight but s2 an...

background: nt-probnp is a marker that is released from ventricles in response to pressure and volume overload. raised plasma level of nt-probnp is seen in ventricular dysfunction, ventricular muscular mass reduction or ventricular ischemia. anthracyclines are widely used in treatment of pediatric cancer but their use is associated with cardiotoxicity which increases mortality and morbidity. we...

Background: NT-proBNP is a marker that is released from ventricles in response to pressure and volume overload. Raised plasma level of NT-proBNP is seen in ventricular dysfunction, ventricular muscular mass reduction or ventricular ischemia. Anthracyclines are widely used in treatment of pediatric cancer but their use is associated with cardiotoxicity which increases mortality and morbidity. We...

Cardiotoxicity is a well-known complication following treatment with anthracyclines. However, they are still widely used in chemotherapy for breast cancer, lymphoma, leukemia, and sarcoma, among others. Patient clinical characteristics, such as age, sex, comorbidities, anthracycline dose and infusion schedule, and the combined anti-cancer agents used, are diverse among cancer types. It is diffi...

Eribulin mesylate has efficacy in patients who have received ≥2 prior chemotherapies for metastatic breast cancer (MBC) including an anthracycline and taxane. Phase 2 trials showed clinical activity and acceptable tolerability of first-line eribulin (HER2- MBC; Study 206) and eribulin plus trastuzumab (HER2+ MBC; Study 208). Prespecified analyses evaluated efficacy by prior anthracycline and/or...

Background Anthracycline-associated cardiomyopathy is a progressive, dose-dependent complication of Anthracycline chemotherapy. The period between Anthracycline therapy and onset of overt heart failure is often years, even decades, and as such Anthracyclines appear to initiate a myocardial injury that remains clinically silent for a substantial period of time. Left ventricular (LV) ejection fra...

BACKGROUND We examined whether dobutamine-stress QT dispersion (QTd) and heart-rate corrected QT dispersion (QTcd) are useful for detecting subclinical anthracycline cardiotoxicity. METHODS The subjects were 10 control subjects and 37 patients divided into 4 groups according to cumulative anthracycline dose: non-anthracycline group (group N), 7 patients; low anthracycline cumulative dose grou...